Biovica International AB (publ)
STO: BIOVIC-B.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Anders Rylander
- Employees
- 26
- Headquarters
- Uppsala, Sweden
- IPO year
- 2017
- Market cap
- SEK 65.7M
- Website
- https://www.biovica.com
Loading BIOVIC-B…
Loading profile data…Frequently asked questions about BIOVIC-B
What does Biovica International AB (publ) (BIOVIC-B.ST) do?
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine...
Where does BIOVIC-B.ST trade?
Biovica International AB (publ) (BIOVIC-B.ST) trades on the Stockholm Stock Exchange.
What sector is BIOVIC-B.ST in?
Biovica International AB (publ) (BIOVIC-B.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Biovica International AB (publ)?
Anders Rylander is the chief executive officer of Biovica International AB (publ) (BIOVIC-B.ST).
Where is Biovica International AB (publ) headquartered?
Biovica International AB (publ) is headquartered in Sweden.
Does BIOVIC-B.ST pay a dividend?
Biovica International AB (publ) (BIOVIC-B.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BIOVIC-B.ST go public?
Biovica International AB (publ) (BIOVIC-B.ST) completed its initial public offering in 2017.